Toggle light / dark theme

Are mouse models relevant to Human regenerative medicine?

To begin with, why do we use mice in medical and biological research? The answer to this question is fairly straight forward. Mice are cheap, they grow quickly, and the public rarely object to experimentations involving mice. However, mice offer something that is far more important than simple pragmatism, as despite being significantly smaller and externally dissimilar to humans, our two species share an awful lot of similarities. Almost every gene found within mice share functions with genes found within humans, with many genes being essentially identical (with the obvious exception of genetic variation found within all species). This means that anatomically mice are remarkably similar to humans.

Now, this is where for the sake of clarity it would be best to break down biomedical research into two categories. Physiological research and pharmaceutical research, as the success of the mouse model should probably be judges separately depending upon the research that is being carried out. Separating the question of the usefulness of the mouse model down into these two categories also solves the function of more accurately focusing the ire of its critics.

The usefulness of the mouse model in the field of physiological research is largely unquestioned at this point. We have quite literally filled entire textbooks with the information we have gained from studying mice, especially in the field of genetics and pathology. The similarities between humans and mice are so prevalent that it is in fact possible to create functioning human/mouse hybrids, known as ‘genetically engineered mouse models’ or ‘GEMMs’. Essentially, GEMMs are mice that have had the mouse version of a particular gene replaced with its human equivalent. This is an exceptionally powerful tool for medical research, and has led to numerous medical breakthroughs, including most notably our current treatment of acute promyelocytic leukaemia (APL), which was created using GEMMs.

Dr. Morten Scheibye-Knudsen — University of Copenhagen — Aging, DNA Repair, And Clinical Innovation

Aging, DNA Repair, And Clinical Innovation — Dr. Morten Scheibye-Knudsen — University of Copenhagen.


Dr. Morten Scheibye-Knudsen is an Associate Professor at the Department of Cellular and Molecular Medicine, and at the Center for Healthy Aging (CEHA), at the University of Copenhagen.

Dr. Scheibye-Knudsen did his MD at the University of Copenhagen and worked briefly as a physician in Denmark and Greenland before turning to science. He did his post-doctoral fellowship at Vilhelm Bohr’s lab at the National Institute on Aging, National Institutes of Health, USA, where he utilized state-of-the art approaches to understand how DNA damage contributes to aging, discovering that neurodegeneration in several premature aging diseases is partly caused by hyperactivation of a DNA damage responsive enzyme called polyADP-ribose polymerase 1 (PARP1). This activation leads to loss of vital metabolites such as Nicotinamide Adenine Dinucleotide (NAD+) and acetyl-CoA. Importantly, this discovery facilitated the realization that we can intervene in the aging process by inhibiting PARP1, augmenting NAD+ levels and increasing acetyl-CoA.

In his own lab Dr. Scheibye-Knudsen continues to focus on understanding aging by combining machine learning based approaches with wet-lab analyses with the goal of developing interventions for age-associated diseases and perhaps aging itself.

Dr. Scheibye-Knudsen is Chief Editor, Frontiers in Aging, and an Advisory Board Member of the Longevity Vision Fund and Molecule Protocol.

Aubrey de Grey: Breakthroughs in Longevity & The Anti-Aging Revolution

Famed longevity pioneer Aubrey de Grey, Chief Science Officer of SENS Research Foundation, joins Geoffrey Woo, Founder and Chairman of Health Via Modern Nutrition Inc., for an enlightening conversation about advances in longevity, the investments and technologies that extend life, and the challenges and opportunities of a world in which people live longer. He walks us through his damage repair therapies with a focus on rejuvenation, prevention, and wearable technologies. Filmed on May 17, 2021. To continue the discussion with fellow Real Vision members on this interview, click here to visit the Exchange: https://rvtv.io/2T7nqZL

Key Learnings: Longevity escape velocity, which is a term de Grey coined, is the idea in which life expectancy is extended longer than the time that is passing, and he estimates a 50% chance that aging could be brought under medical control in as little as 15 years’ time. To learn more about SENS’ research and advancements, please visit their site here: https://www.sens.org/.

Lifespan.io Starting Rapamycin Antiaging Human Trials

Rapamycin has been proven to extend the lifespan of mice, warms and yeast. Lifespan.io is starting a large clinical trial named Participatory Evaluation (of) Aging (with) Rapamycin (for) Longevity Study, or PEARL, to see if the antiaging effects of Rapamycin apply to humans. This will be the first study to see if Rapamycin works as well in humans as it does in mice.

The PEARL trial will follow up to 200 participants over 12 months testing four different Rapamycin dosing regimens. It will be double-blind, randomized, placebo-controlled and registered with clinicaltrials.gov. The principal investigator is Dr. James P Watson at UCLA, who was also a PI for the famous TRIIM trial.

Tests and measurements will be taken, both after 6 and 12 months. These will include autonomic health tests, blood tests, body composition tests, fecal microbiome testing, immune and inflammation health tests, methylation age clock testing and skeletal muscle tests.

Jeff Bezos wants to LIVE FOREVER — Aubrey De Grey: Secret Longevity Investor

Interesting as I recall Aubrey lamenting that he had met Bezos several times over the years but never got a dime from him. Also I wonder where he would put the cash. Just donor all h by is SENS? Pick a company like Age-x?


Jeff Bezos is said to get into the Longevity Industry next month according to Aubrey De Grey. Having a billionaire invest into finding a cure for aging is both amazing and worrisome.
The field of longevity research was long underfunded but recently, with more and more results coming in, investors like Jeff Bezos are getting more and more interested in the field.

Last week, the most prominent figure in the longevity-research community, Aubrey The gray, has announced that one of the biggest event of this community will transpire in around a month. Previous investors were other tech entrepreneur like Peter Thiel or Googles Larry Page.

Every day is a day closer to the Technological Singularity. Experience Robots learning to walk & think, humans flying to Mars and us finally merging with technology itself. And as all of that happens, we at AI News cover the absolute cutting edge best technology inventions of Humanity.

If you enjoyed this video, please consider rating this video and subscribing to our channel for more frequent uploads. Thank you! smile

TIMESTAMPS:
00:00 A Secret Investor?
00:53 Aubrey De Grey Interview.
01:49 The History of Longevity Investors.
04:08 Why invest in Longevity Research.
06:49 Last Words.

#aubreydegrey #longevity #jeffbezos

Is Ageing a disease and can it be CURED? Andrew Steele interview

Hey guys — you might like this interview I did with Alex Steele about counter-ageing and the quest for biological immortality (focused around his new book ‘Ageless: The New Science of Getting Old Without Getting Older’. If you do very grateful for any subs to help support the channel!


I speak with Andrew Steele; author, scientist and anti-ageing campaigner about his book Ageless: The New Science of Getting Old Without Getting Older”. Interview covers why humans age, the growing anti-ageing movement, scientific progress over the past decade and potential anti-ageing treatments.

You can buy Andrew’s book here: https://www.amazon.co.uk/Ageless-Science-Getting-Older-Without/dp/152660826X

Didier Coeurnelle: update on rats lifespan experiments

The third episode of our podcast, ImmortaliCast, is now available! We interviewed Didier Coeurnelle, chair and co-founder of HEALES, and Marion Steenacker, biologist from HEALES, who updated us on the partial results from the lifespan experiments on rats conducted by Harold Katcher and Rodolfo Goya and funded by HEALES. Didier also discusses the more important trends in the rejuvenation field, and the other activities and goals of HEALES.

You can watch this episode via YouTube or on the main podcast platforms:

#science #rejuvenation #aging #medicine #health #heales #lifespan #biology #plasma #HaroldKatcher #RodolfoGoya


In this interview for the podcast ImmortaliCast, Didier Coeurnelle, chair and co-founder of HEALES (https://heales.org/), and Marion Steenacker, biologist from HEALES, update us on the partial results from the lifespan experiments on rats conducted by Harold Katcher and Rodolfo Goya and funded by HEALES (https://heales.org/2020/12/22/studies-financed-by-heales-eff…er-2020/). Didier also discusses the more important trends in the rejuvenation field, and the other activities and goals of HEALES.

The Fable of the Dragon-Tyrant:

VLDL Increases During Aging, And Is Associated With Adverse Cardiovascular Outcomes

Papers referenced in the video:

Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk:
https://www.jacc.org/doi/10.1016/j.jacc.2020.10.

The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling:
https://www.sciencedirect.com/science/article/pii/S0753332220309781

Joint distribution of lipoprotein cholesterol classes. The Framingham study:
https://pubmed.ncbi.nlm.nih.gov/6573877/

Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: the results of a 15-Year Chinese Multi-Provincial Cohort Study (CMCS):
https://pubmed.ncbi.nlm.nih.gov/20223457/

Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease:

/* */